Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that sometimes cause impaired decision-making and poor ... Some Diabetes Drugs Tied to ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, according to research led by Amanda Gusovsky, of Ohio State University ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

BioSpace has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at ...

A new study shows that a common glaucoma drug cleared tau build-up and reduced signs of neurodegenerative disease in zebrafish and mice.

Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease ...